Drug Trial Radar · NCT02204501
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers
Last checked: Nov 19, 2026Latest source record: May 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
May 2014
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Biota Scientific Management Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate. Additionally, the effect of midazolam on the PK profile of vapendavir, a PK profile comparison of vapendavir in males and females, as well as the safety of vapendavir will also be assessed.
Conditions
- Drug-Drug Interaction Healthy Volunteers
Interventions
Midazolam 5mg SyrupDrug
All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days. * On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning. * On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B.
Vapendavir 264 mg BIDDrug
Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
Vapendavir 528 mg QDDrug
Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Effect of Vapendavir on the PK Profile of MidazolamTime frame: End of Study (up to 46 weeks in duration)
- The Effect of Vapendavir on the PK Profile of MidazolamTime frame: End of Study (up to 46 weeks in duration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prism Clinical Research
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.